INO-4800与INO-4802序贯加强接种方案在非人灵长类中增强并拓宽抗SARS-CoV-2免疫应答
本研究在恒河猴中评估新冠DNA疫苗INO-4800与INI-4802作为加强针的免疫原性。动物在初免一年后以同源或异源方案加强,两种方案均扩增T细胞与抗体应答,提升对野生型及多种关注变异株的中和与ACE2阻断活性。
要点
- 初免一年后加强接种仍可扩增T细胞与抗体应答。
- 加强后对野生型及多种关注变异株的中和与ACE2阻断活性改善。
- 同源与异源加强方案均支持使用INO-4800或INO-4802。
核心结论
- INO-4800初免一年后以INO-4800或INO-4802加强均扩增T细胞与抗体应答,并改善对野生型及多种关注变异株的中和与ACE2阻断活性,支持两种疫苗用于序贯加强方案。
研究设计与样本
- 在非人灵长类恒河猴中,以第一代INO-4800疫苗初免超过一年后,分别用INO-4800或INO-4802进行同源或异源加强接种,评估免疫原性。
主要发现
- 两种加强方案均导致T细胞与抗体应答扩增。
- 加强后对野生型SARS-CoV-2及多种关注变异株的中和活性与ACE2阻断活性改善。
关键数值与推荐
- 两种加强方案均扩增T细胞与抗体应答,并改善对野生型及多种关注变异株的中和与ACE2阻断活性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The enhanced transmissibility and immune evasion associated with emerging SARS-CoV-2 variants demands the development of next-generation vaccines capable of inducing superior protection amid a shifting pandemic landscape. Since a portion of the global population harbors some level of immunity from vaccines based on the original Wuhan-Hu-1 SARS-CoV-2 sequence or natural infection, an important question going forward is whether this immunity can be boosted by next-generation vaccines that target emerging variants while simultaneously maintaining long-term protection against existing strains. Here, we evaluated the immunogenicity of INO-4800, our synthetic DNA vaccine candidate for COVID-19 currently in clinical evaluation, and INO-4802, a next-generation DNA vaccine designed to broadly target emerging SARS-CoV-2 variants, as booster vaccines in nonhuman primates. Rhesus macaques primed over one year prior with the first-generation INO-4800 vaccine were boosted with either INO-4800 or INO-4802 in homologous or heterologous prime-boost regimens. Both boosting schedules led to an expansion of T cells and antibody responses which were characterized by improved neutralizing and ACE2 blocking activity across wild-type SARS-CoV-2 as well as multiple variants of concern. These data illustrate the durability of immunity following vaccination with INO-4800 and additionally support the use of either INO-4800 or INO-4802 in prime-boost regimens.
引用
- Walters JN, Schouest B, Patel A, et al. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. Vaccine. 2022. PMID: 35428500. doi:10.1016/j.vaccine.2022.03.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。